Auris, nasus, larynx · 2026
Age-stratified clinical interpretation of AWGS2025 sarcopenia criteria in head and neck cancer treated with definitive chemoradiotherapy: Comparison with AWGS2019.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kitoh Ryosuke, Iwasa Yoh-Ichiro, Yokota Yoh, Hori Kentaro, Okubo Takuya, Takumi Yutaka
Аннотация
OBJECTIVE: The AWGS2025 update extends sarcopenia diagnosis to adults aged 50-64 years, requires concurrent low muscle mass and low muscle strength, and introduces BMI-stratified muscle mass thresholds. We aimed to examine how these changes alter case identification in patients with head and neck cancer (HNC) undergoing definitive chemoradiotherapy (CRT).
METHODS: We retrospectively analyzed 97 consecutive patients with HNC who underwent pretreatment assessment before definitive CRT. AWGS2025 was applied to patients aged ≥ 50 years, and AWGS2019 and AWGS2025 were cross-classified in those aged ≥ 65 years. We compared agreement, treatment selection, cisplatin completion, and selected acute toxicities in age-stratified analyses.
RESULTS: Among patients aged ≥ 65 years (n = 55), sarcopenia prevalence was 23.6% by AWGS2019 and 20.0% by AWGS2025, with substantial agreement (κ = 0.79). In older adults, discordance was driven mainly by removal of physical performance from the diagnostic algorithm. Among triCDDP-treated older adults, the clearest acute-toxicity signal in sarcopenic patients was grade ≥ 3 radiation dermatitis. AWGS2025 additionally classified 6/35 (17.1%) patients aged 50-64 years as sarcopenic. In this small subgroup, treatment intensity and selected acute toxicities were not clearly increased.
CONCLUSION: In HNC treated with definitive CRT, AWGS2025 represents an age-stratified diagnostic reclassification rather than a replacement for AWGS2019. In older adults, an AWGS2025 diagnosis may identify patients at increased risk of selected acute toxicities, particularly severe radiation dermatitis, whereas its clinical meaning in middle-aged adults remains exploratory.
METHODS: We retrospectively analyzed 97 consecutive patients with HNC who underwent pretreatment assessment before definitive CRT. AWGS2025 was applied to patients aged ≥ 50 years, and AWGS2019 and AWGS2025 were cross-classified in those aged ≥ 65 years. We compared agreement, treatment selection, cisplatin completion, and selected acute toxicities in age-stratified analyses.
RESULTS: Among patients aged ≥ 65 years (n = 55), sarcopenia prevalence was 23.6% by AWGS2019 and 20.0% by AWGS2025, with substantial agreement (κ = 0.79). In older adults, discordance was driven mainly by removal of physical performance from the diagnostic algorithm. Among triCDDP-treated older adults, the clearest acute-toxicity signal in sarcopenic patients was grade ≥ 3 radiation dermatitis. AWGS2025 additionally classified 6/35 (17.1%) patients aged 50-64 years as sarcopenic. In this small subgroup, treatment intensity and selected acute toxicities were not clearly increased.
CONCLUSION: In HNC treated with definitive CRT, AWGS2025 represents an age-stratified diagnostic reclassification rather than a replacement for AWGS2019. In older adults, an AWGS2025 diagnosis may identify patients at increased risk of selected acute toxicities, particularly severe radiation dermatitis, whereas its clinical meaning in middle-aged adults remains exploratory.